Compare Quest Diagnostics Inc (DGX) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Mercadolibre Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Mercadolibre Inc trades at $1,880 (market cap $95.00B). The key difference: Mercadolibre Inc is far larger — about 4.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| DGX | MELI | |
|---|---|---|
Market Cap | $22.80B | $95.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $2.51K |
52-Week Low | $166.42 | $1.55K |
Enterprise Value | $28.82B | $101.89B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MercadoLibre (MELI) trades at $1,867.30, up 0.81% today, with a bullish technical signal and strong analyst support. Recent financials show robust revenue growth to $28.89 billion in 2025, though net income margins compressed to 6.04%. The stock faces near-term pressure from three consecutive quarterly EPS misses but benefits from expanding cash flow and a dominant position in Latin American e-commerce and fintech.
Outlook remains positive with a consensus price target of $2,230, implying 19% upside, but risks include margin volatility from heavy investments and competitive threats. Institutional sentiment is strong with 72% buy ratings, though high P/E of 49.28 demands sustained growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
